SCHEMBL7806086

SCHEMBL7806086

CC(=O)OC[C@H]1O[C@@H](n2c(Br)nc3cc(Cl)c(Cl)cc32)[C@H](O)[C@@H]1O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC15A1 P46059 1/20 0.66
HDAC6 Q9UBN7 1/20 0.52
ALDH1A1 P00352 2/20 0.38
LMNA P02545 2/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
HSPA5 P11021 2/20 0.35
ADORA2B P29275 1/20 0.34
HSPA2 P54652 1/20 0.33
NADK O95544 1/20 0.33
THRB P10828 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HIF1A Q16665 1/20 0.33
PNP P00491 1/20 0.33
CCNT1 O60563 1/20 0.33
CCNK O75909 1/20 0.33
CDK7 P50613 1/20 0.33
CDK9 P50750 1/20 0.33
CCNH P51946 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7806081 1.00 SLC15A1 (0.66) SLC15A1HDAC6ALDH1A1LMNATP53
SCHEMBL8176532 0.89 SLC15A1 (0.54) SLC15A1HDAC6ALDH1A1LMNATP53
SCHEMBL3545846 0.86 ALDH1A1 (0.54) SLC15A1HDAC6ALDH1A1LMNATP53
SCHEMBL3547093 0.86 ALDH1A1 (0.54) SLC15A1HDAC6ALDH1A1LMNATP53
SCHEMBL3545841 0.86 ALDH1A1 (0.54) SLC15A1HDAC6ALDH1A1LMNATP53
SCHEMBL30860092 0.85 SLC15A1 (0.51) SLC15A1HDAC6ALDH1A1LMNATP53
SCHEMBL8626734 0.83 SLC15A1 (0.49) SLC15A1HDAC6ALDH1A1LMNATP53
SCHEMBL8367473 0.82 HDAC6 (0.69) SLC15A1HDAC6LMNATP53MAPT
SCHEMBL7635326 0.82 HDAC6 (0.69) SLC15A1HDAC6LMNATP53MAPT
SCHEMBL7639605 0.82 HDAC6 (0.69) SLC15A1HDAC6LMNATP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6307043-B1 FOR TREATMENT OR PROPHYLAXIS OF HERPES VIRAL INFECTIONS GLAXO WELLCOME INC. 2001-10-23 US disclosed
US-20010003744-A1 Therapeutic compounds CHAMBERLAIN STANLEY DAWES (US) 2001-06-14 US disclosed
US-6093698-A 1-(2',3',5'-TRIACETYL-BETA-D-RIBOFURANOSYL),2-BROMO,5,6-DICHLORO -BENZIMIDAZOLE OR 1-(5'-ACETYL-BETA-D-RIBOFURANOSYL),2-BROMO,5,6-DICHLORO-BENZIMIDAZOLE; TREATING HERPES VIRAL INFECTIONS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2000-07-25 US disclosed
US-6077832-A FOR THERAPY AND PROPHYLAXIS OF HERPES VIRUS INFECTION GLAXO WELLCOME INC. (US) 2000-06-20 US disclosed
EP-0769017-B1 THERAPEUTIC COMPOUNDS WELLCOME FOUND (GB) 2000-05-24 EP disclosed
US-5998605-A Antiviral benzimidazole nucleoside analogues and method for their preparation GLAXO WELLCOME INC. (US) 1999-12-07 US disclosed
US-5712255-A VIRICIDES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1998-01-27 US disclosed
US-5705490-A TREATMENT OF HERPES OR CYTOMEGALOVIRUS WITH BENZIMIDAZOLE DERIATIVES THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1998-01-06 US disclosed
US-5665709-A FOR TREATING A HERPES VIRAL INFECTION THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1997-09-09 US disclosed
US-5654283-A HERPES VIRUS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1997-08-05 US disclosed
US-5646125-A Polysubstituted benzimidazoles as antiviral agents THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1997-07-08 US disclosed
US-5574058-A Polysubstituted benzimidazoles as antiviral agents THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1996-11-12 US disclosed
WO-1996001833-A1 THERAPEUTIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1996-01-25 WO disclosed
EP-0556334-A4 POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS UNIV MICHIGAN (US) 1995-03-29 EP disclosed
US-5360795-A Treating cytomegalo virus and herpes simplex viruses THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1994-11-01 US disclosed
WO-1994008456-A1 POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1994-04-28 WO disclosed
EP-0556334-A1 POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1993-08-25 EP disclosed
WO-1992007867-A1 POLYSUBSTITUTED BENZIMIDAZOLES AS ANTIVIRAL AGENTS THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 1992-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010003744-A1 Therapeutic compounds ZC3HAV1, HAVCR2, EIF2AK2 SLC15A1 3489/4885HDAC6 78/4885ALDH1A1 269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.